Diabetic Retinopathy Treatment Market Size 2022: Worldwide Industry Report | Forecast To 2027

Rising incidence of diabetic retinopathy around the globe will be the key factor driving the global diabetic retinopathy treatment market growth. According to the research conducted on vision loss in 2017 under the Global Burden of Disease Study, diabetic retinopathy caused visual impairment in 2.6 million people worldwide. By 2020, this number is expected to rise to 3.2 million. Diabetic retinopathy is one of the most common microvascular disorder caused by diabetes mellitus. Increasing prevalence of diabetes will further accelerate the spread of this complication. The International Diabetes Federation estimates that approximately 463 million people the world over are suffering from diabetes currently and this number will almost double to reach 700 million by 2045. This steadily climbing rate of this chronic disease will augment the diabetic retinopathy treatment market size during the forecast period.

Request a Sample Copy of Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/diabetic-retinopathy-treatment-market-101153

Fortune Business Insights™ provides the above information in its report, titled "Diabetic Retinopathy Treatment Market Size, Share and Global Trend By Diabetic Retinopathy Type (Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy), By Treatment Type (Anti-Vascular Endothelial Growth Factor (VEGF) Drug, Laser Surgery, Vitrectomy, Intraocular Steroid Injection), By End User (Hospitals, Ophthalmic Centres, Ambulatory Surgery Centres, Others) and Geography Forecast till 2026". Moreover, the report contains the following:

Valuable insights into the different market dynamics such as competitive landscape and regional developments;
Thorough research into the various segments of the market;
Elaborative overview of the general industry trends; and
Detailed analysis of the factors and drivers influencing the growth of the market in the given period.
Availability of Advanced Treatment Options to Boost Market Prospects

Diabetic retinopathy is an affliction which occurs when a person's blood vessels in the retina get damaged due to high blood sugar level. It is a common condition faced by diabetics and intensive research has led to the development of excellent therapeutic options for patients. For example, in case of severe diabetic maculopathy, anti-VEGF injections are administered directly into the eyes to prevent the formation of new blood vessels in the back of the eyes. Similarly, to treat advanced stages of diabetic retinopathy, laser treatment is available which can repair the damaged blood vessels in the eyes. The procedure takes up only 40 to 50 minutes and the patient need not stay in the hospital overnight, thus saving her additional costs. The introduction of these easy-to-access and relatively affordable treatments is expected to be one of the leading diabetic retinopathy treatment market trends in the near future.

Well-Established Healthcare Infrastructure to Fuel the Market in North America

Among regions, North America is anticipated to dominate the diabetic retinopathy treatment market share owing to a robust healthcare and insurance system which ensures that patients have uninterrupted access to high-quality medical facilities. Furthermore, the market is foreseen to rise at an impressive rate owing to the increasing incidence of diabetes in the region. On the other hand, Asia-Pacific will exhibit the fastest growth rate owing to the evolving healthcare systems and increasing disposable income in the region.

Governmental Support to New Products to Open the Floodgates of Innovation

According to the diabetic retinopathy treatment market analysis, the competitive landscape in this market is highly-charged as a result of presence of a few key players and the strategies they are adopting to strengthen their position. Their efforts at innovation are bearing sweet fruits as governments are providing the required regulatory support that is necessary for market competition to thrive.

Key Industry Developments:

April 2018: IDx Technologies developed the first Artificial Intelligence-based diagnostic tool for diabetic retinopathy patients, which got approved by the US FDA. This system enables detection of diabetic retinopathy among patients during regular clinic visits.
March 2018: Allergan launched Ozurdex in China to treat adult patients with diabetic macular edema and Retinal Vision Occlusion (RVO), which is the second most common type of retinal vascular disorder.
Top Players Covered in the Diabetic Retinopathy Treatment Market Report:



Regeneron Pharmaceuticals, Inc.
Oxurion NV
Novartis AG
Hoffmann-La Roche Ltd.
Pfizer Inc.
Alimera Sciences
Bayer AG
Abbott

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™, we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune - 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

This release was published on openPR.